DUSP2.md
... ...
@@ -30,8 +30,8 @@ timeline
30 30
|Entity|Tier|Description |
31 31
|:------:|:----:|--------------------------------------|
32 32
|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@dunsCharacterizationDLBCLPMBL2021b]|
33
-|![DLBCL](images/icons/DLBCL_tier1.png) |1-a | aSHM target and high-confidence DLBCL gene [@morinMutationalStructuralAnalysis2013][@lohrDiscoveryPrioritizationSomatic2012a]|
34
-|![FL](images/icons/FL_tier2.png) |2-a | aSHM target; Although recurrent, the relevance of mutations in FL is tenuous |
33
+|![DLBCL](images/icons/DLBCL_tier1.png) |1 | aSHM target and high-confidence DLBCL gene [@morinMutationalStructuralAnalysis2013; @lohrDiscoveryPrioritizationSomatic2012a]|
34
+|![FL](images/icons/FL_tier2.png) |2 | aSHM target; Although recurrent, the relevance of mutations in FL is tenuous |
35 35
36 36
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
37 37